News

Eli Lilly says diabetes therapy Mounjaro leads to heart benefits in late-stage trial
Eli Lilly (NYSE:LLY) announced Thursday that its diabetes therapy, Mounjaro (tirzepatide), succeeded in a late-stage trial ...
Biogen lifts full-year outlook amid Alzheimer’s drug strength, sending shares up
Investing.com - Shares of Biogen (NASDAQ:BIIB) rose in premarket U.S. trading on Thursday after the drugmaker posted ...
Eli Lilly's Mounjaro shows heart health benefits in head-to-head trial with older diabetes drug Trulicity
Eli Lilly said it believes the new data bolsters the case for Mounjaro to be prescribers’ first choice for patients with Type ...
Cantech Letter17m
RESEARCH ADVANCES FROM THE 2025 ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE
New research results reported at the Alzheimer’s Association International Conference® 2025 (AAIC®) advanced scientific understanding of risk, diagnosis and treatment ...